Literature DB >> 30535920

CRAX: A simple cardiovascular risk assessment tool to predict risk of acute myocardial infarction or death.

Patrick Martineau1,2, Piotr Slomka3, Andrew Goertzen1, William D Leslie4,5.   

Abstract

BACKGROUND: Determining the risk of cardiovascular events is essential to optimize patient management. METHODS AND
RESULTS: 5842 individuals underwent SPECT myocardial perfusion imaging (MPI) with 4.4 ± 1.2 years of follow-up. Models (the CRAX tool) were derived to predict the cumulative risk of death and acute myocardial infarction (AMI) at 1, 3, and 5 years using clinical and MPI variables. Predictors of AMI and death included age, number of hospitalizations in the 3 years preceding MPI, and left ventricular ejection fraction (LVEF). Additional predictors of death were the use of pharmacological stress, and global stress total perfusion deficit (sTPD), while transient ischemic dilation (TID), and ischemic total perfusion deficit (iTPD) change were predictive of AMI. CRAX predictions were significantly (P < .001) more accurate than clinical variables or MPI results alone, resulting in a significant net reclassification improvement (NRI, 7.5% for AMI, 14.5% death) compared to clinical variables alone. Accuracy for predicting major adverse cardiac events (MACE, comprising all-cause death, AMI, unstable angina, late revascularization) was comparable to that of AMI or death.
CONCLUSIONS: CRAX is a risk assessment tool that predicts the risk of AMI, death, or MACE, and improves prediction compared to clinical variables or MPI results alone.

Entities:  

Keywords:  Myocardial perfusion imaging; acute myocardial infarction; gated SPECT; prognosis

Mesh:

Year:  2018        PMID: 30535920      PMCID: PMC6565497          DOI: 10.1007/s12350-018-01556-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  33 in total

1.  Improved near-term coronary artery disease risk classification with gated stress myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Peter W F Wilson; Rory Hachamovitch; Robert C Hendel; Salvador Borges-Neto; Daniel S Berman
Journal:  JACC Cardiovasc Imaging       Date:  2010-11

2.  Simplified normal limits and automated quantitative assessment for attenuation-corrected myocardial perfusion SPECT.

Authors:  Piotr J Slomka; Mathews B Fish; Santiago Lorenzo; Hidetaka Nishina; James Gerlach; Daniel S Berman; Guido Germano
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

3.  Automated quantification of myocardial perfusion SPECT using simplified normal limits.

Authors:  Piotr J Slomka; Hidetaka Nishina; Daniel S Berman; Cigdem Akincioglu; Aiden Abidov; John D Friedman; Sean W Hayes; Guido Germano
Journal:  J Nucl Cardiol       Date:  2005 Jan-Feb       Impact factor: 5.952

4.  Validation of an electronic, population-based prescription database.

Authors:  A L Kozyrskyj; C A Mustard
Journal:  Ann Pharmacother       Date:  1998-11       Impact factor: 3.154

5.  Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients : study in 1137 patients with 6-year follow-up.

Authors:  G Vanzetto; O Ormezzano; D Fagret; M Comet; B Denis; J Machecourt
Journal:  Circulation       Date:  1999-10-05       Impact factor: 29.690

6.  Prognostic value of automated quantification of 99mTc-sestamibi myocardial perfusion imaging.

Authors:  William D Leslie; Shawn A Tully; Marina S Yogendran; Linda M Ward; Khaled A Nour; Colleen J Metge
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  Comparative prognostic value of automatic quantitative analysis versus semiquantitative visual analysis of exercise myocardial perfusion single-photon emission computed tomography.

Authors:  D S Berman; X Kang; K F Van Train; H C Lewin; I Cohen; J Areeda; J D Friedman; G Germano; L J Shaw; R Hachamovitch
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

8.  High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography.

Authors:  J J Mahmarian; L A Moyé; M S Verani; M F Bloom; C M Pratt
Journal:  Am J Cardiol       Date:  1995-06-01       Impact factor: 2.778

9.  Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification.

Authors:  R Hachamovitch; D S Berman; H Kiat; I Cohen; J A Cabico; J Friedman; G A Diamond
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

10.  Prognostic Value of Combined Clinical and Myocardial Perfusion Imaging Data Using Machine Learning.

Authors:  Julian Betancur; Yuka Otaki; Manish Motwani; Mathews B Fish; Mark Lemley; Damini Dey; Heidi Gransar; Balaji Tamarappoo; Guido Germano; Tali Sharir; Daniel S Berman; Piotr J Slomka
Journal:  JACC Cardiovasc Imaging       Date:  2017-10-18
View more
  5 in total

1.  Cardiovascular risk assessment models: Have we found the perfect solution yet?

Authors:  Aiden Abidov; Omar Chehab
Journal:  J Nucl Cardiol       Date:  2019-02-21       Impact factor: 5.952

2.  Adding value to myocardial perfusion scintigraphy: A prediction tool to predict adverse cardiac outcomes and risk stratify.

Authors:  Ricardo A Nieves; Syed Bukhari; Matthew E Harinstein
Journal:  J Nucl Cardiol       Date:  2021-06-24       Impact factor: 5.952

Review 3.  Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications.

Authors:  Piotr J Slomka; Jonathan B Moody; Robert J H Miller; Jennifer M Renaud; Edward P Ficaro; Ernest V Garcia
Journal:  J Nucl Cardiol       Date:  2020-10-16       Impact factor: 5.952

4.  Prediction of 2-year major adverse cardiac events from myocardial perfusion scintigraphy and clinical risk factors.

Authors:  William D Leslie; Mark Bryanton; Andrew Goertzen; Piotr Slomka
Journal:  J Nucl Cardiol       Date:  2021-04-28       Impact factor: 3.872

5.  Advanced technology in the risk stratification-based strategy: The way forward to keep going.

Authors:  Roberta Assante; Emilia Zampella; Wanda Acampa
Journal:  J Nucl Cardiol       Date:  2020-06-12       Impact factor: 5.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.